image description

Press Releases

Press Releases

November 12, 2019
Revance to Participate in the Stifel 2019 Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,
November 6, 2019
Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare
November 4, 2019
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
– Conference call and webcast today at 4:30 p.m. ET – NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the
October 14, 2019
Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne
- Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of glabellar lines in the Fall of 2019, as previously announced - NEWARK, Calif.
October 2, 2019
Revance Earns Great Place to Work® Certification for Second Year
  NEWARK, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at
September 25, 2019
Revance to Participate in the 2019 Cantor Global Healthcare Conference
  NEWARK, Calif. --(BUSINESS WIRE)--Sep. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare
Displaying 1 - 10 of 183